Posted in | News | Nanomedicine | Nanomaterials

Intezyne Soon to Receive European Patent for IVECT Nanoparticle Method

Intezyne today announced it has received notification the European Patent Office intends to grant a patent covering a key element of Intezyne’s breakthrough drug delivery technology, the IVECT™ Method.

At the core of this technology is the IVECT micelle, a proprietary, polymeric nanoparticle designed to encapsulate and deliver best-in-class therapeutics, while limiting exposure to healthy tissues. The IVECT Method is already covered by seven additional patents both in the United States and worldwide. This wide-ranging, European patent covers technology that allows greater flexibility and versatility of the IVECT micelle, particularly with respect to the amount of hydrophobic material that can be encapsulated into this drug delivery vehicle, further bolstering Intezyne’s intellectual property portfolio.

Hybrid Block Copolymers With Mixed Stereochemistry for Encapsulation of Hydrophobic Agents

  -  Sill, K.; Skaff, H.; Breitenkamp, K.
   -  EU patent number: EP2073850
   -  Issued claims include composition of matter for Intezyne’s proprietary triblock
      copolymers, which utilize both D- and L-isomers in the encapsulation block.

“Historically, encapsulating highly hydrophobic drugs has proven to be a major stumbling block for the great majority of drug delivery systems,” explained Kevin Sill, Ph.D., Chief Scientific Officer of Intezyne. “The advanced technology covered by this patent protects Intezyne’s ability to encapsulate hydrophobic drugs more efficiently. Further, we have shown for the first time IVECT micelles are able to encapsulate several hydrophobic compounds that were previously intractable to delivery methods at therapeutically relevant levels.”

Intezyne is active in its efforts to prosecute its patents and protect its intellectual property in major global pharmaceutical markets. The above patent currently is being prosecuted in the United States, as well as Australia, Canada, Israel, India, Japan, Mexico, and New Zealand.

All granted and pending patent applications are wholly owned by Intezyne.

Source: http://www.intezyne.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.